CN109757730B - Composition with functions of reducing blood fat, blood pressure and blood sugar and preparation method thereof - Google Patents
Composition with functions of reducing blood fat, blood pressure and blood sugar and preparation method thereof Download PDFInfo
- Publication number
- CN109757730B CN109757730B CN201910101340.6A CN201910101340A CN109757730B CN 109757730 B CN109757730 B CN 109757730B CN 201910101340 A CN201910101340 A CN 201910101340A CN 109757730 B CN109757730 B CN 109757730B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus rhamnosus
- powder
- parts
- composition
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a composition for reducing blood fat, blood pressure and blood sugar, which takes lactobacillus rhamnosus bacterium powder and lactobacillus rhamnosus metabolite powder as active ingredients. The lactobacillus rhamnosus is preserved in China center for type culture Collection with the preservation number: CCTCC NO: m2018299. Embodiments of the present invention also provide a method for preparing the composition, which comprises: and (3) carrying out expanded strain culture, primary seed culture, seed tank culture and fermentation culture on the lactobacillus rhamnosus to obtain lactobacillus rhamnosus fermentation liquor. The composition for reducing blood fat, blood pressure and blood sugar provided by the embodiment of the invention can effectively reduce blood fat, blood pressure and blood sugar of a human body, has no toxic or side effect, and has the advantages of simple preparation method and low manufacturing cost.
Description
Technical Field
The invention relates to the technical field of application of microbial thalli, and particularly relates to a composition capable of reducing blood fat, blood pressure and blood sugar and a preparation method thereof.
Background
Hypertension is a common cardiovascular disease, has high morbidity, is often accompanied by functional or organic changes of organs such as heart, blood vessels, lung, kidney and the like, and is an important risk factor for causing various complications such as heart, brain, kidney, eye blood vessels and the like, stroke, atherosclerosis and coronary heart disease. Due to the factors of increased probability of eating outside and refined diet, the modern people have excessive caloric intake and fat accumulation in the body, so that the condition of hyperlipidemia is easy to occur. According to research, hyperlipidemia is indicated to be not only prone to fatty liver or atherosclerosis but also an important risk factor for hypertension, heart disease, cerebral stroke, diabetes, arteriosclerosis, kidney disease, and the like.
Probiotic bacteria, which are non-pathogenic microorganisms that survive in the intestinal tract, help protect the inner wall of the intestinal tract from damage, ameliorate the associated side effects of antibiotics, such as gastroenteritis, acute diarrhea, and also ameliorate the symptoms of lactose intolerance. The probiotics gradually become an important product for preventing and treating diseases and maintaining health, and has the short-term effect of taking effect quickly, such as the effects of preventing and treating acute and chronic diarrhea and constipation, improving the functions of intestines and stomach and the like; the liver protecting tea also has obvious long-term effects, such as effects of protecting the liver and assisting in improving symptoms of liver diseases by reducing the endotoxin level of a human body, improving the nutritional status, helping the growth of liver cells, improving the immunity of the human body and the like; the probiotic bacteria can also improve the symptoms of dysbacteriosis caused by side effects in chemical, radiation and immunosuppressant treatment, such as appetite reduction, debilitation, leukocyte count reduction, etc., and improve disease resistance.
At present, the way of taking natural extracts as main raw materials to achieve the effect of reducing blood fat is increasingly favored by consumers, and the obtaining of the natural extracts needs a large amount of traditional Chinese medicine raw materials and has high manufacturing cost; on the other hand, it is not ideal in lowering blood pressure, blood fat and blood sugar. In addition, the Western medicines can reduce the blood pressure, blood fat and blood sugar of the human body, and have certain side effects on the human body although the Western medicines can play certain effects.
Therefore, the traditional raw materials and medicines for reducing the three highs have the defects of complicated preparation method, poor treatment effect and side effect. Therefore, a composition with good effects of significantly reducing blood pressure and blood lipid, regulating blood sugar and improving kidney is urgently needed.
Disclosure of Invention
The embodiment of the invention aims to provide a composition capable of reducing blood fat, blood pressure and blood sugar and a preparation method thereof, and aims to overcome the defects of complicated preparation method, poor treatment effect and large toxic and side effects of the traditional medicine.
In order to achieve the above objects, the present invention provides a composition for reducing blood lipid, blood pressure and blood sugar, which comprises lactobacillus rhamnosus powder and lactobacillus rhamnosus metabolite powder as active ingredients.
Preferably, the lactobacillus rhamnosus is preserved in the China center for type culture Collection with the preservation number: CCTCC NO: m2018299.
Preferably, the composition also comprises a fungus powder carrier, wherein the fungus powder carrier comprises microcrystalline cellulose, medicinal corn starch, inulin and magnesium stearate;
the composition comprises the following raw materials in parts by weight: 9-11 parts of lactobacillus rhamnosus powder, 4-6 parts of lactobacillus rhamnosus metabolite powder, 18-22 parts of microcrystalline cellulose, 80-120 parts of medicinal corn starch, 8-12 parts of inulin and 8-12 parts of magnesium stearate.
Preferably, the composition comprises the following raw materials in parts by mass: 9.5-10.5 parts of lactobacillus rhamnosus thallus, 4.5-5.5 parts of lactobacillus rhamnosus metabolite, 19-21 parts of microcrystalline cellulose, 90-110 parts of medicinal corn starch, 9-11 parts of inulin and 9-11 parts of magnesium stearate.
Embodiments of the present invention also provide a method for preparing the composition, which comprises:
carrying out expanded strain culture, primary seed culture, seed tank culture and fermentation culture on the lactobacillus rhamnosus to obtain lactobacillus rhamnosus fermentation liquor;
centrifuging the lactobacillus rhamnosus fermentation liquor, respectively collecting lactobacillus rhamnosus bacterial sludge and the centrifuged fermentation liquor, and freeze-drying and crushing the lactobacillus rhamnosus bacterial sludge and the centrifuged fermentation liquor to obtain lactobacillus rhamnosus bacterial powder and lactobacillus rhamnosus metabolite powder;
and mixing the lactobacillus rhamnosus bacterium powder, the lactobacillus rhamnosus metabolite powder and a bacterium powder carrier to obtain the composition.
Preferably, the preparation method of the lactobacillus rhamnosus bacterial powder specifically comprises the following steps:
and mixing the lactobacillus rhamnosus bacterial sludge, sterile water, skimmed milk powder, fructo-oligosaccharide, glycerol, maltodextrin and isomaltose hypgather to obtain lactobacillus rhamnosus suspended bacterium liquid, and freeze-drying and crushing the suspended bacterium liquid to obtain lactobacillus rhamnosus bacterial powder.
Preferably, the suspension liquid is pre-frozen for 2 to 5 hours at the temperature of between 35 ℃ below zero and 30 ℃ below zero, is subjected to vacuum freeze drying at the temperature of between 50 ℃ below zero and 40 ℃ below zero, and is crushed into 100-mesh lactobacillus rhamnosus powder.
Preferably, the centrifuged fermentation liquid is subjected to low-temperature concentration to obtain a fermentation liquid concentrated paste with the water content of at most 20%, and the fermentation liquid concentrated paste and the medicinal corn starch are mixed in a ratio of 5: 1-4: 1 to obtain a mixture, then drying the mixture for 40 to 50 hours at the temperature of 55 to 60 ℃, and crushing the mixture to obtain the lactobacillus rhamnosus metabolite powder with the water content of at most 3 percent.
The compositions prepared in the embodiments of the present invention also provide applications in preparing products having at least one of the following functions:
1) lowering blood pressure;
2) reducing blood fat;
3) reducing blood sugar;
4) enhancing immunity.
The embodiment of the invention has the following advantages:
the composition for reducing blood fat, blood pressure and blood sugar provided by the embodiment of the invention can effectively reduce blood fat, blood pressure and blood sugar of a human body, has no toxic or side effect, and has the advantages of simple preparation method and low manufacturing cost.
Detailed Description
The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention.
In the embodiment of the invention, a new strain is obtained by strain screening, is separated from fresh citrus epidermis, is obtained by primary screening and secondary screening, is identified as Lactobacillus rhamnosus (Lactobacillus rhamnosus +11) by 16S DNA, is subjected to biological preservation, and is preserved in the China center for type culture collection in 2018, month 05 and day 21 at the preservation address of: the preservation numbers of Wuhan university, Wuhan university in China are as follows: CCTCC NO: m2018299. The nucleotide sequence of the strain is shown as SEQ ID 1.
Example 1
One, expanding strain culture
Strain: lactobacillus rhamnosus of embodiments of the present invention; equipment used in production: a strain incubator, an ultra-clean workbench, a constant-temperature incubator, various test tubes, a triangular flask, a seeding tank, a fermentation tank, a vacuum freeze dryer, a three-dimensional stirrer, a low-temperature crusher and a vacuum packaging machine.
Carrying out expanded culture on a lactobacillus rhamnosus strain stored at the temperature of-80 ℃, wherein a culture medium for the expanded culture is prepared by the following steps: 18 g of glucose, 8 g of peptone, 10g of beef extract powder, 4 g of sodium acetate, 801 ml of tween, 1 g of urea and 1000ml of water, and the pH value is natural.
Adding glucose and other raw materials in the above enlarged strain culture medium formula into 1000ml of water, stirring for 30min to dissolve, then subpackaging in 18 x 180 test tubes, each test tube containing 10ml, sealing with rubber plug kraft paper, sterilizing in a medical sterilizer at 0.1-0.12 MPa for 25min, and completing culture medium sterilization.
Taking out a freezing tube with lactobacillus rhamnosus stored at-80 ℃ under an aseptic condition, melting at room temperature, taking 1 count of the sterilized test tube strain culture medium for enlarged culture, adding 1ml of the melted-80 ℃ storage bacterium liquid into the test tube, sealing the tube opening with a rubber plug and kraft paper, shaking up gently, putting the test tube into a constant temperature incubator, and standing and culturing at 37 ℃ for 12 hours to obtain an enlarged strain culture solution.
Second and first order seed culture
The formula of a culture medium for first-stage seed culture comprises the following components: 20 g of glucose, 10g of peptone, 8 g of beef extract powder, 4 g of corn steep liquor, 4 g of sodium acetate, 801 ml of Tween and 1000ml of water, and the pH value is natural.
Adding the above raw materials into water for preparing culture medium, stirring for 20min to dissolve the raw materials completely to obtain first-stage seed culture solution. Adding the first-class seed culture solution into triangular flask according to dosage, binding the triangular flask with 6 layers of gauze and one layer of kraft paper, sterilizing in medical sterilizer, opening exhaust valve on sterilizer before sterilization, closing when a small amount of steam is exhausted, opening exhaust valve on sterilizer when the pressure on sterilizer reaches 0.05 MPa, exhausting for 6-8min, closing exhaust valve, heating, timing when the steam pressure in sterilizer reaches 0.1-0.12 MPa, sterilizing for 25min, leaving heat source, naturally cooling, opening sterilizer when the pressure gauge on sterilizer is zero, taking out sterilized culture medium, cooling in superclean bench, transferring expanded strain into sterilized triangular flask culture solution when the temperature is reduced to 37 deg.C, the inoculum size is 1%, the method comprises inoculating 1ml of expanded bacterial solution into 100ml of primary seed culture solution, sealing the opening of a triangular flask with original gauze and kraft paper after inoculation, slightly shaking with hand to uniformly mix the inoculated strain and the culture solution, and culturing in a constant temperature oven at 37 deg.C for 12 hr to obtain primary bacterial solution.
Third, seeding tank culture
Sterilizing fermentation equipment, pipelines and a sterile filtration system, firstly opening valves of all inlet and outlet pipelines and a sterile air pipeline of the fermentation equipment, introducing 0.12-0.14 MPa steam, communicating the steam with the pipeline valves and discharging a small amount of steam, introducing the steam for 40min, keeping the steam pressure in the pipelines at 0.12-0.14 MPa for 40min, and then closing all the inlet and outlet pipeline valves for later use.
Closing valves of the seed tank and the fermentation tank, opening a drain valve at the bottom of the tank and a drain valve in an interlayer of the tank, opening a direct steam valve to introduce 0.12-0.14 MPa steam into the tank, starting timing when the temperature in the tank reaches 121 ℃, sterilizing for 40min, then closing the drain valve at the bottom of the tank and the drain valve in the interlayer, and naturally cooling the temperature in the seed tank and the fermentation tank to 37 ℃ for later use.
Wherein, the formula of the culture medium in the seeding tank is as follows: 8% of glucose, 2% of peptone, 0.5% of urea, 0.3% of dipotassium phosphate, 2% of corn steep liquor, 0.2% of sodium acetate, 800.4% of tween, 3% of polydextrose, 0.1% of polyether defoamer, 83.5% of water and natural pH value.
Firstly, putting water used in a seed tank culture medium formula into a seed tank sterilized in an empty tank, starting a stirrer, respectively adding raw materials required in the seed tank culture medium formula, then introducing steam for heating in continuous stirring, firstly heating to 95 ℃ by utilizing interlayer steam of the seed tank, then directly heating by using the steam, keeping the temperature in the seed tank for 30min when the temperature reaches 121 ℃, thus achieving the sterilization effect, then closing the steam, beginning to cool and cool by the water of the tank interlayer, and keeping standby when the temperature in the tank reaches 37 ℃, thus obtaining the seed tank culture medium.
Inoculating the cultured first-stage strain liquid into a seed tank culture medium under an aseptic condition, wherein the inoculation amount is 1% of the culture medium in the seed tank respectively, namely 100 kg of the seed tank culture medium is inoculated with 1 kg of the first-stage strain liquid respectively. Then covering an inoculation cap on the seeding tank, starting to stir the culture medium of the seeding tank, wherein the culture conditions are as follows: the temperature is 37 ℃, the pH value is natural, the stirring speed is 80 r/min, the tank pressure is 0.05 MPa, the culture time is 20 hours, if the tank pressure of the seeding tank is reduced, sterile air can be introduced to maintain the tank pressure, and if the tank pressure is too high, the tank pressure can be adjusted by using a gas release valve on the tank top, so that the strains in the seeding tank are obtained.
Thirdly, fermentation culture of strains
The fermentation medium comprises the following components in percentage by weight: 10% of glucose, 1% of peptone, 2% of polydextrose, 10% of isomaltose hypgather, 1% of sodium acetate, 800.2% of tween, 4% of potato starch, 0.5% of conjugated linoleic acid, 0.2% of anhydrous calcium chloride, 0.5% of magnesium sulfate, 4% of corn steep liquor, 0.1% of polyether defoamer and 66.5% of water, wherein the total amount is 100 kg. Firstly, putting water required in the culture medium preparation process into a fermentation tank sterilized in an empty tank, starting a stirrer, putting raw materials used in a formula into the fermentation tank, then introducing steam for heating, firstly, heating to 95 ℃ by using interlayer steam, then, heating by using direct steam, starting timing when the temperature in the fermentation tank reaches 121 ℃, keeping for 30min, thus achieving the sterilization effect, then cooling by using water in an interlayer of the fermentation tank, starting inoculating strains when the temperature in the fermentation tank is reduced to 37 ℃, firstly, increasing the tank pressure of the fermentation tank to 0.1 MPa, keeping the tank pressure of the fermentation tank to 0.05 MPa, then, opening an inoculation pipeline valve, conveying the strains cultured in a seed tank into the fermentation tank by means of pressure difference, and then closing the inoculation pipeline valve.
The inoculation amount of the fermentation tank is 3 kg of strains cultured in an inoculation seed tank in every 100 kg of culture medium of the fermentation tank, and the fermentation conditions are as follows: the fermentation temperature is 37 ℃, the stirring speed is 120 r/min, the fermentation time is 16 hours, the pressure of the fermentation tank is kept at 0.05 MPa, the pH value is natural, if the pressure of the fermentation tank is reduced, sterile air can be introduced to keep the pressure of the fermentation tank, and if the pressure of the fermentation tank is too high, the pressure can be adjusted by an exhaust valve at the top of the fermentation tank, so that the lactobacillus rhamnosus fermentation liquor is obtained.
The lactobacillus rhamnosus fermentation liquor is centrifuged, the wet lactobacillus rhamnosus sludge is collected, after the fermentation is finished, the fermentation liquor is pumped into a storage tank, and the selection of the centrifugal rotating speed is very important in order to ensure the integrity of thalli in the fermentation liquor. Starting a tubular centrifuge, adjusting the rotating speed to 12000 r/min, centrifuging at a feeding speed of 15 kg per minute, collecting wet lactobacillus rhamnosus bacterial sludge after centrifugation is finished, freeze-drying the centrifugally collected wet bacterial sludge, concentrating the centrifuged fermentation liquor at a low temperature in vacuum, adding a carrier, and compounding a finished product after vacuum drying.
Fourthly, freeze drying of lactobacillus rhamnosus bacterial mud
1. Preparation of suspension liquid
1000 g of wet bacterial sludge is taken and added with 3000ml of sterile distilled water, 300 g of skim milk powder, 200 g of fructo-oligosaccharide, 100ml of 98% glycerol, 50 g of maltodextrin and 300 g of isomalto-oligosaccharide.
Firstly, heating 1500ml of water to 50-55 ℃, adding maltodextrin under the condition of stirring, adding the rest water after dissolution, then adding other raw materials in the formula, fully stirring for 30min at the temperature of 25-35 ℃ to form a suspension liquid, and then placing the suspension liquid into a thermostatic chamber or a box at the temperature of 30 ℃ for thermostatic 30min for pre-freezing. Pre-freezing before freeze drying, namely sub-packaging the suspension liquid with constant temperature for 30min into a freeze drying tray, then pre-freezing the suspension liquid in a pre-freezing chamber of a freeze dryer for 3 hours at the temperature of minus 30-35 ℃, and vacuumizing and drying after freezing.
And putting the pre-frozen material tray into a vacuum drying chamber to begin vacuum drying under the conditions that the vacuum degree is 2-5 Pa, the temperature is-45 ℃, the temperature of the drying chamber is 28 ℃ and the drying time is 45 hours. And after freeze-drying, collecting freeze-dried materials, crushing the freeze-dried materials into bacterial powder with the fineness of 100 meshes by using an aseptic crusher, and sealing and packaging the bacterial powder for later use to obtain the lactobacillus rhamnosus bacterial powder.
2. Low temperature concentration of centrifugal fermentation broth
Centrifuging the concentrated fermentation liquor under vacuum degree of 0.06 MPa and temperature of 55-65 deg.C, concentrating to obtain paste with solid content of 80% and water content of 20%, mixing, and vacuum drying. Taking 1000 g of fermentation liquor concentrated paste, adding 200 g of medicinal corn starch, uniformly mixing, and drying in a vacuum drying oven, wherein the drying conditions are as follows: drying at 55-60 deg.C under 0.06 MPa for 45 hr until the water content is 3%, pulverizing to 100 mesh powder, and sealing and packaging to obtain Lactobacillus rhamnosus metabolite powder. Wherein the mass fraction ratio of the fermentation liquor concentrated paste to the medicinal corn starch is 5: 1-4: 1.
3. the embodiment of the invention has the compounding of the composition finished product for reducing blood fat, blood pressure and blood sugar: 5g of lactobacillus rhamnosus powder of 100 meshes, 3 g of lactobacillus rhamnosus metabolite powder, 10g of microcrystalline cellulose, 20 g of medicinal corn starch, 5g of inulin and 5g of magnesium stearate are taken.
The materials are put into a solid stirring mixer to be uniformly mixed, and then are subpackaged into capsules under the aseptic condition, and the composition with the functions of reducing blood fat, blood pressure and blood sugar is obtained by bottling or tabletting.
Example 2
The embodiment of the invention has the compounding of the composition finished product for reducing blood fat, blood pressure and blood sugar: 9 g of lactobacillus rhamnosus powder of 100 meshes, 6 g of lactobacillus rhamnosus metabolite powder, 22 g of microcrystalline cellulose, 120 g of medicinal corn starch, 12 g of inulin and 12 g of magnesium stearate are taken.
Wherein the lactobacillus rhamnosus bacterium powder and the lactobacillus rhamnosus metabolite powder are both the lactobacillus rhamnosus bacterium powder and the lactobacillus rhamnosus metabolite powder prepared in the method of example 1.
Example 3
The embodiment of the invention has the compounding of the composition finished product for reducing blood fat, blood pressure and blood sugar: 9 g of lactobacillus rhamnosus powder of 100 meshes, 4 g of lactobacillus rhamnosus metabolite powder, 22 g of microcrystalline cellulose, 120 g of medicinal corn starch, 8 g of inulin and 8 g of magnesium stearate are taken.
Wherein the lactobacillus rhamnosus bacterium powder and the lactobacillus rhamnosus metabolite powder are both the lactobacillus rhamnosus bacterium powder and the lactobacillus rhamnosus metabolite powder prepared in the method of example 1.
Example 4
The embodiment of the invention has the compounding of the composition finished product for reducing blood fat, blood pressure and blood sugar: taking 11 g of 100-mesh lactobacillus rhamnosus powder, 6 g of lactobacillus rhamnosus metabolite powder, 18 g of microcrystalline cellulose, 80 g of medicinal corn starch, 8 g of inulin and 8 g of magnesium stearate.
Wherein the lactobacillus rhamnosus bacterium powder and the lactobacillus rhamnosus metabolite powder are both the lactobacillus rhamnosus bacterium powder and the lactobacillus rhamnosus metabolite powder prepared in the method of example 1.
Example 5
The embodiment of the invention has the compounding of the composition finished product for reducing blood fat, blood pressure and blood sugar: taking 11 g of 100-mesh lactobacillus rhamnosus powder, 6 g of lactobacillus rhamnosus metabolite powder, 18 g of microcrystalline cellulose, 80 g of medicinal corn starch, 12 g of inulin and 12 g of magnesium stearate.
Wherein the lactobacillus rhamnosus bacterium powder and the lactobacillus rhamnosus metabolite powder are both the lactobacillus rhamnosus bacterium powder and the lactobacillus rhamnosus metabolite powder prepared in the method of example 1.
Example 6
The embodiment of the invention has the compounding of the composition finished product for reducing blood fat, blood pressure and blood sugar: taking 10.5 g of lactobacillus rhamnosus powder of 100 meshes, 5.5 g of lactobacillus rhamnosus metabolite powder, 19 g of microcrystalline cellulose, 100 g of medicinal corn starch, 9.5 g of inulin and 10g of magnesium stearate.
Wherein the lactobacillus rhamnosus bacterium powder and the lactobacillus rhamnosus metabolite powder are both the lactobacillus rhamnosus bacterium powder and the lactobacillus rhamnosus metabolite powder prepared in the method of example 1.
Comparative example 1
Chinese patent document CN105641209A the probiotic composition with the function of improving immunity prepared by the method of example 3 is marked as composition D, and is dissolved in water for taking, wherein each person takes 15g every time and three times a day.
Comparative example 2
Chinese patent document CN105725185A the probiotic composition with the function of improving immunity prepared by the method of example 1 is marked as composition M, and is dissolved in water for taking, 15g for each time, three times a day for each person.
Test example
1 examples 2-6 stability effect verification of composition having blood lipid, blood pressure and blood sugar lowering effects
The conditions for preserving the microbial inoculum of the composition with the effect of reducing blood fat, blood pressure and blood sugar prepared in the examples 2 to 6 are as follows:
1) anaerobic and sealing;
2) storing in shade at normal temperature (25-30 ℃);
3) sun protection;
4) the maximum temperature can not exceed 45 ℃ above zero, and can be stored for 12 months.
2 the composition having hypolipidemic, hypotensive and hypoglycemic effects prepared in examples 2 to 6
2.1 Experimental instruments and materials
Hitachi 7020 full-automatic biochemical detector.
2.2 design of the experiment
540 cases of hyperlipidemia were selected and divided into 6 groups of 90 persons each using the compositions prepared in examples 2-6 and composition D, respectively; the following patients were excluded: (1) suffering from malignant diseases, such as tumor, severe heart, liver, and kidney diseases; thyroid disease; (2) the lipid-lowering drugs were taken within 1 month before the start of the experiment.
During the experiment, the subjects can keep the diet and living habits as unlimited as possible and can not take lipid-lowering medicines.
The test products of the examples of the present invention were administered to the 540 subjects half an hour after breakfast, lunch and dinner each day, and the administration of the comparative examples was performed as described in the comparative examples. The medicine is taken continuously for 3 months, and the diet is not restricted and the life style is not changed in the rest time.
The effect of each group was evaluated by the patient's own control in this experiment.
2.3 detection of indicators
Before and at the end of the experiment, the following physical indicators were measured for each group: total cholesterol, triglycerides, high density cholesterol, low density cholesterol.
The change of any biochemical index of the patient in self contrast before and after the experiment is more than 1 percent and marked as effective, more than 5 percent and less than 1 percent are marked as ineffective.
2.3 evaluation criteria
And (3) curing: the clinical symptoms substantially improve or disappear entirely after treatment;
the method has the following advantages: the clinical symptoms improved after treatment;
and (4) invalidation: the symptoms are not significantly reduced or exacerbated.
2.4 results of the experiment
The results of the experiments for each group are shown in table 1.
TABLE 1 results of the experiments on reducing blood lipid
As can be seen from Table 1: the composition of the invention has obvious improvement effect on reducing blood fat.
Among 90 patients, the effective case of the composition D in reducing blood fat is 48, the cure rate is 4, and the total effective rate is 53.3%.
2.5 conclusion of the experiment
The composition provided by the embodiment of the invention has a remarkable blood fat reducing effect.
3. The composition with the functions of reducing blood fat, blood pressure and blood sugar provided by the embodiment of the invention has the functions of reducing blood pressure and blood sugar
3.1 general data
The trial was selected to receive the composition with reduced blood lipid, blood pressure and blood glucose with a total of 600 patients with hypertension, hyperglycemia at 2015 6 months-2018 month 7, wherein treatment 1 group: 200 middle-aged and elderly men, age 30-70 years, average age 52 years; treatment 2 groups: 200 middle-aged and elderly women, age 32-68 years, average age 56 years; a control group of 200 persons, with an average age of 30 years, was used as the study subject. The difference of the basic data of each group of patients, such as sex, age, disease type and the like, has no statistical significance (P is more than 0.05) and is comparable.
3.2 evaluation criteria
And (3) curing: the clinical symptoms substantially improve or disappear entirely after treatment;
the method has the following advantages: the clinical symptoms improved after treatment;
and (4) invalidation: the symptoms are not significantly reduced or exacerbated.
3.3 methods of treatment
Treatment groups 1-2: the compositions with the functions of reducing blood fat, blood pressure and blood sugar of the examples 2 to 3 are respectively supplied to patients for taking 1 time per day, each time taking 1 dose/10 g, each gram of the lactobacillus rhamnosus contains 50 hundred million/CFU of live lactobacillus casei.
Control group: the composition M of comparative example 1 was administered to the patients 1 time a day at 1 dose/10 g.
3.4 results
After 30 days of treatment, the results of comparison of clinical treatment effects of the two groups are shown in Table 2
TABLE 2
Description of the drawings: the statistical effect starts when 200 men take the medicine for 3 days, and 65 men who take the medicine for 3 days and have different ages improve the blood pressure and the blood sugar, and relieve the symptoms of dizziness, fatigue and the like; after the medicine is taken for 9 days, the blood pressure and the blood sugar of 122 people are reduced by detection; after the medicine is taken for 15 days, 165 people have obvious blood pressure and blood sugar reduction, and symptoms such as dizziness, fatigue and the like are obviously improved; after taking the medicine for 30 days, 150 people recover normal values of blood pressure and blood sugar, symptoms such as dizziness, fatigue and the like are relieved, and 44 people have a certain degree of relief. During the test period, the blood pressure and the blood sugar of 6 people are not reduced after taking the lactobacillus rhamnosus.
The statistical effect starts when 200 women take the medicine for 3 days, and 78 people who take the medicine for 3 days and have different ages improve the blood pressure and the blood sugar, and relieve the symptoms of dizziness, fatigue and the like; after the medicine is taken for 9 days, 133 people have blood pressure and blood sugar reduced by detection; after the medicine is taken for 15 days, 168 people have obvious blood pressure and blood sugar reduction, and symptoms such as dizziness, fatigue and the like are obviously improved; after being taken for 30 days, 142 people recover normal values of blood pressure and blood sugar, symptoms such as dizziness, fatigue and the like are relieved, and 50 people improve the symptoms to a certain extent. In the test period, the blood pressure and the blood sugar of 8 people are not reduced after taking the lactobacillus rhamnosus.
In the comparative example, 200 people begin to count the effect after taking the medicine for 3 days, and 40 people with different ages after taking the medicine for 3 days are detected to improve the blood pressure and the blood sugar and relieve the symptoms of dizziness, fatigue and the like; after the medicine is taken for 9 days, 80 people have reduced blood pressure and blood sugar through detection; after the medicine is taken for 15 days, the blood pressure and the blood sugar of 98 people are obviously reduced, and the symptoms such as dizziness, fatigue and the like are obviously improved; after the medicine is taken for 30 days, 86 people recover normal values of blood pressure and blood sugar, symptoms such as dizziness, fatigue and the like are relieved, and 23 people have a certain degree of relief. During the test period, 91 people have no reduction in blood pressure and blood sugar after taking lactobacillus rhamnosus.
Although the invention has been described in detail above with reference to a general description and specific examples, it will be apparent to one skilled in the art that modifications or improvements may be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.
Sequence listing
<110> Shandong Huanyi Biotechnology Ltd
<120> a composition for reducing blood fat, blood pressure and blood sugar and a preparation method thereof
<130> GG18158542A
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1460
<212> DNA
<213> Lactobacillus rhamnosus
<400> 1
cacattagac ggctcgctcc ctaaaagggt tacgccaccg gcttcgggtg ttacaaactc 60
tcatggtgtg acgggcggtg tgtacaaggc ccgggaacgt attcaccgcg gcgtgctgat 120
ccgcgattac tagcgattcc gacttcgtgt aggcgagttg cagcctacag tccgaactga 180
gaatggcttt aagagattag cttgacctcg cggtctcgca actcgttgta ccatccattg 240
tagcacgtgt gtagcccagg tcataagggg catgatgatt tgacgtcatc cccaccttcc 300
tccggtttgt caccggcagt cttactagag tgcccaacta aatgctggca actagtcata 360
agggttgcgc tcgttgcggg acttaaccca acatctcacg acacgagctg acgacaacca 420
tacaccacct gtcattttgc ccccgaaggg gaaacctgat ctctcaggtg atcaaaagat 480
gtcaagacct ggtaaggttc ttcgcgttgc ttcgaattaa accacatgct ccaccgcttg 540
tgcgggcccc cgtcaattcc tttgagtttc aaccttgcgg tcgtactccc caggcggaat 600
gcttaatgcg ttagctgcgg cactgaaggg gggaaaccct ccaacaccta gcattcatcg 660
tttacggcat ggactaccag ggtatctaat cctgttcgct acccatgctt tcgagcctca 720
gcgtcagtta cagaccagac agccgccttc gccactggtg ttcttccata tatctacgca 780
tttcaccgct acacatggag ttccactgtc ctcttctgca ctcaagtttc ccagtttccg 840
atgcacttcc tcggttaagc cgagggcttt cacatcagac ttaaaaaacc gcctgcgctc 900
gctttacgcc caataaatcc ggataacgct tgccacctac gtattaccgc ggctgctggc 960
acgtagttag ccgtggcttt ctggttggat accgtcacgc cgacaacagt tactctgccg 1020
accattcttc tccaacaaca gagttttacg acccgaaagc cttcttcact cacgcggcgt 1080
tgctccatca gacttgcgtc cattgtggaa gattccctac tgctgcctcc cgtaggagtt 1140
tgggccgtgt ctcagtccca atgtggccga tcaacctctc agttcggcta cgtatcattg 1200
ccttggtgag ccgttacctc accaactagc taatacgccg cgggtccatc caaaagcgat 1260
agcttacgcc atctttcagc caagaaccat gcggttcttg gatttatgcg gtattagcat 1320
ctgtttccaa atgttatccc ccacttaagg gcaggttacc cacgtgttac tcacccgtcc 1380
gccactcgtt caaaattaaa tcaagatgca agcacctttc aataatcaga actcgttcga 1440
ctgcagtata gcatgccgcc 1460
Claims (6)
1. A composition with the functions of reducing blood fat, blood pressure and blood sugar is characterized in that lactobacillus rhamnosus bacterium powder and lactobacillus rhamnosus metabolite powder are taken as active ingredients; the lactobacillus rhamnosus is preserved in China center for type culture Collection with the preservation number: CCTCC NO: m2018299; the composition also comprises a fungus powder carrier, wherein the fungus powder carrier comprises microcrystalline cellulose, medicinal corn starch, inulin and magnesium stearate; the composition comprises the following raw materials in parts by weight: 9-11 parts of lactobacillus rhamnosus powder, 4-6 parts of lactobacillus rhamnosus metabolite powder, 18-22 parts of microcrystalline cellulose, 80-120 parts of medicinal corn starch, 8-12 parts of inulin and 8-12 parts of magnesium stearate.
2. The composition of claim 1, wherein the composition comprises the following raw materials in parts by mass: 9.5-10.5 parts of lactobacillus rhamnosus thallus, 4.5-5.5 parts of lactobacillus rhamnosus metabolite, 19-21 parts of microcrystalline cellulose, 90-110 parts of medicinal corn starch, 9-11 parts of inulin and 9-11 parts of magnesium stearate.
3. A method of preparing the composition of claim 1 or 2, comprising: carrying out expanded strain culture, primary seed culture, seed tank culture and fermentation culture on the lactobacillus rhamnosus to obtain lactobacillus rhamnosus fermentation liquor; centrifuging the lactobacillus rhamnosus fermentation liquor, respectively collecting lactobacillus rhamnosus bacterial sludge and the centrifuged fermentation liquor, and freeze-drying and crushing the lactobacillus rhamnosus bacterial sludge and the centrifuged fermentation liquor to obtain lactobacillus rhamnosus bacterial powder and lactobacillus rhamnosus metabolite powder; and mixing the lactobacillus rhamnosus bacterium powder, the lactobacillus rhamnosus metabolite powder and a bacterium powder carrier to obtain the composition.
4. The method of claim 3, wherein the preparation method of the Lactobacillus rhamnosus bacterial powder specifically comprises the following steps: and mixing the lactobacillus rhamnosus bacterial sludge, sterile water, skimmed milk powder, fructo-oligosaccharide, glycerol, maltodextrin and isomaltose hypgather to obtain lactobacillus rhamnosus suspended bacterium liquid, and freeze-drying and crushing the suspended bacterium liquid to obtain lactobacillus rhamnosus bacterial powder.
5. The method of claim 4, wherein the suspension liquid is freeze-dried at-35 ℃ to-30 ℃ for 2-5 hours, vacuum freeze-dried at-50 ℃ to-40 ℃ and crushed into 100-mesh lactobacillus rhamnosus powder.
6. Use of a composition prepared by the method of claim 3 in the preparation of a product having at least one of the following functions: 1) lowering blood pressure; 2) reducing blood fat; 3) reducing blood sugar; 4) enhancing immunity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910101340.6A CN109757730B (en) | 2019-01-31 | 2019-01-31 | Composition with functions of reducing blood fat, blood pressure and blood sugar and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910101340.6A CN109757730B (en) | 2019-01-31 | 2019-01-31 | Composition with functions of reducing blood fat, blood pressure and blood sugar and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109757730A CN109757730A (en) | 2019-05-17 |
| CN109757730B true CN109757730B (en) | 2021-06-04 |
Family
ID=66455938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910101340.6A Active CN109757730B (en) | 2019-01-31 | 2019-01-31 | Composition with functions of reducing blood fat, blood pressure and blood sugar and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109757730B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023079276A1 (en) * | 2021-11-03 | 2023-05-11 | Iiaa Limited | Compositions comprising probiotic and postbiotic strains of bacteria |
Citations (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1555815A (en) * | 2004-01-10 | 2004-12-22 | 内蒙古双奇药业股份有限公司 | Method of bological transforming selenium using bacillus bifidus and its product |
| CN1781950A (en) * | 2005-09-09 | 2006-06-07 | 天津市工业微生物研究所 | Method for producing extracellular mucopoly-saccharide using rhamnose lactobacillus and product |
| CN101328470A (en) * | 2008-07-09 | 2008-12-24 | 扬州大学 | Rhamnose bacterium lacticum grx10 having cholesterol lowering and antibacterial functions, preparation and use thereof |
| CN101496822A (en) * | 2009-02-18 | 2009-08-05 | 上海谱莱生物技术有限公司 | Composite probiotics micro-ecological formulation and preparation method |
| CN102215848A (en) * | 2007-08-10 | 2011-10-12 | 雀巢产品技术援助有限公司 | Lactobacillus rhamnosus and weight control |
| CN102316880A (en) * | 2009-02-10 | 2012-01-11 | 雀巢产品技术援助有限公司 | Lactobacillus rhamnosus ncc4007, a probiotic mixture and weight control |
| CN102316881A (en) * | 2009-02-10 | 2012-01-11 | 雀巢产品技术援助有限公司 | Lactobacillus rhamnosus cncm i-4096 and weight control |
| CN102453681A (en) * | 2011-12-15 | 2012-05-16 | 北京大北农科技集团股份有限公司 | Protective agent for vacuum freeze drying of lactobacillus johnsonii, and application thereof |
| CN103275905A (en) * | 2013-05-31 | 2013-09-04 | 江南大学 | Lactobacillus rhamnosus CCFM0528 having diabetes preventing effect |
| CN103689595A (en) * | 2013-12-12 | 2014-04-02 | 天津科技大学 | Soft lactic acid bacteria capsule and preparation method thereof |
| CN104095180A (en) * | 2013-04-12 | 2014-10-15 | 中国科学院烟台海岸带研究所 | Probiotics inulin sheet and preparation method thereof |
| CN104560790A (en) * | 2014-12-15 | 2015-04-29 | 北京农学院 | Functional lactobacillus plantarum and preparation method of compound bacterial powder of functional lactobacillus plantarum |
| CN104789488A (en) * | 2014-03-09 | 2015-07-22 | 黑龙江大学 | Lactobacillus rhamnosus having cholesterol lowering effect, and uses thereof |
| CN104870632A (en) * | 2012-11-12 | 2015-08-26 | 热尔韦·达诺尼公司 | Use of lactobacillus rhamnosus strain for reducing weight gain and/or insulin resistance |
| CN104955467A (en) * | 2012-11-12 | 2015-09-30 | 热尔韦·达诺尼公司 | Lactobacillus rhamnosus strain for reducing body fat accumulation |
| CN105018379A (en) * | 2015-07-16 | 2015-11-04 | 山东凤凰生物有限公司 | Lactobacillus plantarum with high antioxidant activity and application of lactobacillus plantarum |
| CN105543126A (en) * | 2015-12-25 | 2016-05-04 | 西北农林科技大学 | Lactobacillus plantarum JM113 and application thereof |
| CN105567590A (en) * | 2015-12-30 | 2016-05-11 | 山东环亿生物科技有限公司 | Enzymatic hydrolysis preparation technology of bifidobacteria and lactic acid bacteria mixed fermented bacteria and application thereof |
| CN108823125A (en) * | 2018-06-13 | 2018-11-16 | 山东巴元生物科技有限公司 | A kind of production method and application for treating sleep disturbance probiotics preparation |
| CN109055278A (en) * | 2018-09-17 | 2018-12-21 | 山东中科嘉亿生物工程有限公司 | A kind of Lactobacillus rhamnosus JYLR-005 and its hypoglycemic product and application |
| CN109123297A (en) * | 2018-08-09 | 2019-01-04 | 润盈生物工程（上海）有限公司 | A kind of probiotic powder solid beverage of advantageous glycemic index decline |
-
2019
- 2019-01-31 CN CN201910101340.6A patent/CN109757730B/en active Active
Patent Citations (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1555815A (en) * | 2004-01-10 | 2004-12-22 | 内蒙古双奇药业股份有限公司 | Method of bological transforming selenium using bacillus bifidus and its product |
| CN1267561C (en) * | 2004-01-10 | 2006-08-02 | 内蒙古双奇药业股份有限公司 | Method of bological transforming selenium using bacillus bifidus and its product |
| CN1781950A (en) * | 2005-09-09 | 2006-06-07 | 天津市工业微生物研究所 | Method for producing extracellular mucopoly-saccharide using rhamnose lactobacillus and product |
| CN102215848A (en) * | 2007-08-10 | 2011-10-12 | 雀巢产品技术援助有限公司 | Lactobacillus rhamnosus and weight control |
| CN101328470A (en) * | 2008-07-09 | 2008-12-24 | 扬州大学 | Rhamnose bacterium lacticum grx10 having cholesterol lowering and antibacterial functions, preparation and use thereof |
| CN102316880A (en) * | 2009-02-10 | 2012-01-11 | 雀巢产品技术援助有限公司 | Lactobacillus rhamnosus ncc4007, a probiotic mixture and weight control |
| CN102316881A (en) * | 2009-02-10 | 2012-01-11 | 雀巢产品技术援助有限公司 | Lactobacillus rhamnosus cncm i-4096 and weight control |
| CN101496822A (en) * | 2009-02-18 | 2009-08-05 | 上海谱莱生物技术有限公司 | Composite probiotics micro-ecological formulation and preparation method |
| CN102453681A (en) * | 2011-12-15 | 2012-05-16 | 北京大北农科技集团股份有限公司 | Protective agent for vacuum freeze drying of lactobacillus johnsonii, and application thereof |
| CN104955467A (en) * | 2012-11-12 | 2015-09-30 | 热尔韦·达诺尼公司 | Lactobacillus rhamnosus strain for reducing body fat accumulation |
| CN104870632A (en) * | 2012-11-12 | 2015-08-26 | 热尔韦·达诺尼公司 | Use of lactobacillus rhamnosus strain for reducing weight gain and/or insulin resistance |
| CN104095180A (en) * | 2013-04-12 | 2014-10-15 | 中国科学院烟台海岸带研究所 | Probiotics inulin sheet and preparation method thereof |
| CN103275905A (en) * | 2013-05-31 | 2013-09-04 | 江南大学 | Lactobacillus rhamnosus CCFM0528 having diabetes preventing effect |
| CN103689595A (en) * | 2013-12-12 | 2014-04-02 | 天津科技大学 | Soft lactic acid bacteria capsule and preparation method thereof |
| CN104789488A (en) * | 2014-03-09 | 2015-07-22 | 黑龙江大学 | Lactobacillus rhamnosus having cholesterol lowering effect, and uses thereof |
| CN104560790A (en) * | 2014-12-15 | 2015-04-29 | 北京农学院 | Functional lactobacillus plantarum and preparation method of compound bacterial powder of functional lactobacillus plantarum |
| CN105018379A (en) * | 2015-07-16 | 2015-11-04 | 山东凤凰生物有限公司 | Lactobacillus plantarum with high antioxidant activity and application of lactobacillus plantarum |
| CN105543126A (en) * | 2015-12-25 | 2016-05-04 | 西北农林科技大学 | Lactobacillus plantarum JM113 and application thereof |
| CN105567590A (en) * | 2015-12-30 | 2016-05-11 | 山东环亿生物科技有限公司 | Enzymatic hydrolysis preparation technology of bifidobacteria and lactic acid bacteria mixed fermented bacteria and application thereof |
| CN108823125A (en) * | 2018-06-13 | 2018-11-16 | 山东巴元生物科技有限公司 | A kind of production method and application for treating sleep disturbance probiotics preparation |
| CN109123297A (en) * | 2018-08-09 | 2019-01-04 | 润盈生物工程（上海）有限公司 | A kind of probiotic powder solid beverage of advantageous glycemic index decline |
| CN109055278A (en) * | 2018-09-17 | 2018-12-21 | 山东中科嘉亿生物工程有限公司 | A kind of Lactobacillus rhamnosus JYLR-005 and its hypoglycemic product and application |
Non-Patent Citations (1)
| Title |
|---|
| 用于降血糖的乳酸菌研究进展;孟晓，等;《食品研究与开发》;20160331;第37卷(第06期);第193-196页 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023079276A1 (en) * | 2021-11-03 | 2023-05-11 | Iiaa Limited | Compositions comprising probiotic and postbiotic strains of bacteria |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109757730A (en) | 2019-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106834187B (en) | Bifidobacterium bifidum and application thereof | |
| CN108823125A (en) | A kind of production method and application for treating sleep disturbance probiotics preparation | |
| CN109588726B (en) | Lactobacillus casei composition for improving sleep and preparation method thereof | |
| CN111607538A (en) | Lactobacillus rhamnosus and application thereof in inhibiting helicobacter pylori | |
| JP2007518693A (en) | Stable liquid probiotic composition, its preparation and application | |
| CN111548970B (en) | Lactobacillus crispatus capable of preventing and/or treating helicobacter pylori infection | |
| CN107164263A (en) | A kind of adjustable function of intestinal canal, the lactobacillus fermenti HY01 for preventing colitis and application thereof | |
| CN109609420B (en) | Helicobacter pylori-resistant probiotic composition and preparation method thereof | |
| CN110150669A (en) | A kind of probiotic composition and its application suitable for patients with diabetes mellitus | |
| CN116731891B (en) | Bifidobacterium breve B2798 and application thereof in preparation of probiotic preparation | |
| CN115838676A (en) | Traditional Chinese medicine fermentation by using novel lactobacillus plantarum strain and application | |
| CN111471626A (en) | Lactobacillus helveticus capable of inhibiting helicobacter pylori and application thereof | |
| CN117327631B (en) | Lactobacillus plantarum strain 10A-2 for improving anxiety and depression and application thereof | |
| CN117343879B (en) | Lactobacillus plantarum 9A-11 and application thereof in preparation of autism improvement products | |
| CN113122472B (en) | Bacteroides vulgatus capable of protecting intestinal permeability and application thereof | |
| CN109757730B (en) | Composition with functions of reducing blood fat, blood pressure and blood sugar and preparation method thereof | |
| CN116555102B (en) | Lactobacillus plantarum producing gamma-aminobutyric acid, sleep-aiding probiotic composition and preparation method thereof | |
| CN111035661A (en) | Application of lactobacillus plantarum | |
| CN109924507B (en) | Probiotics composition for conditioning emotion and preparation method thereof | |
| CN105274032B (en) | A kind of antagonism campylobacter jejuni and the lactobacillus reuteri for inhibiting its flaA gene expression | |
| CN116509905A (en) | Bifidobacterium bifidum biological preparation with constipation relieving effect | |
| CN109846044B (en) | Probiotic composition with functions of improving memory and enhancing immunity and preparation method thereof | |
| CN112043723B (en) | Application of bacillus amyloliquefaciens exopolysaccharide | |
| CN110938563B (en) | Lactobacillus BJ-REBORN001 and application thereof in preparation of helicobacter pylori inhibiting fermentation broth | |
| CN109700033B (en) | Probiotic composition for regulating intestinal tract and preventing constipation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |